Understanding the TNBC Neoadjuvant Chemotherapy Response

Achieving a pathological complete response (pCR) significantly improves the prognosis for patients with triple-negative breast cancer (TNBC). Clinicians are increasingly interested in the TNBC neoadjuvant chemotherapy response because it often varies between the primary tumor and the lymph nodes. A recent systematic review highlights these differences, offering insights that could eventually change surgical management for this aggressive subtype. Specifically, the researchers compared how the breast and axillary lymph nodes react to treatment before surgery.

The systematic review found that nodal pathological complete response (NpCR) occurs more frequently than breast pathological complete response (BpCR) in TNBC patients. For instance, the mean prevalence of BpCR was 32%, while NpCR reached 38.3%. Interestingly, no study reported higher breast response compared with nodal response. This consistent trend suggests that the axilla might be more sensitive to chemotherapy than the primary breast tumor in TNBC cases. Therefore, evaluating these specific response patterns is essential for personalizing patient care.

Clinical Implications for Surgical De-escalation

Currently, surgical evaluation of the axilla remains a mandatory part of breast cancer staging and treatment. However, the higher NpCR rates observed in the TNBC neoadjuvant chemotherapy response data suggest a potential path toward omitting axillary surgery in the future. If clinicians can reliably predict which patients have cleared nodal disease, they might reduce surgical morbidity. Furthermore, identifying predictive biomarkers will be vital to ensure that omitting surgical evaluation does not compromise patient safety or long-term outcomes.

In conclusion, the discrepancy between breast and nodal responses provides a foundation for future clinical trials. Although tumor subtype is a major driver, other biological factors likely influence these patterns. Consequently, ongoing research continues to refine how we manage TNBC to maximize survival while minimizing invasive procedures.

Frequently Asked Questions

Is NpCR more common than BpCR in TNBC?

Yes, research indicates that lymph nodes often show a higher rate of pathological complete response than the primary breast tumor after neoadjuvant chemotherapy.

Why is this response difference clinically significant?

Because the nodal response is often more favorable, researchers are exploring whether certain patients can safely avoid invasive axillary surgery after chemotherapy.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Cristófalo MM et al. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Systematic Review of Breast and Node Pathologic Response. J Surg Oncol. 2026 Feb 15. doi: 10.1002/jso.70213. PMID: 41691697.

2. Kim J et al. Assessing Axillary Pathologic Complete Response in Triple-Negative Breast Cancer. 2024 San Antonio Breast Cancer Symposium. Abstract #SESS-1044.

3. De Graaf M et al. Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study. ESMO Open. 2025 Dec 5;10(12):105923. doi: 10.1016/j.esmoop.2025.105923.